Ching-Lan Lu

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

Mechanisms of SARS-CoV-2 entry into cells

Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

Inflammation and Cancer: Triggers, Mechanisms, and Consequences

mRNA vaccines — a new era in vaccinology

HIV persists throughout deep tissues with repopulation from multiple anatomical sources

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies

The trinity of COVID-19: immunity, inflammation and intervention

SARS-CoV-2 variants, spike mutations and immune escape

Novel Approaches Towards a Functional Cure of HIV/AIDS

A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response

Development of therapeutic antibodies for the treatment of diseases

Double-slit photoelectron interference in strong-field ionization of the neon dimer

Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?

Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development

Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization

Germline‐targeting immunogens

Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody

Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia

Progress toward active or passive HIV-1 vaccination

Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

Relationship between intact HIV-1 proviruses in circulating CD4 ⁺ T cells and rebound viruses emerging during treatment interruption

Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir